Moleculin Biotech, Inc. filed a Form 8-K on September 23, 2026, disclosing a Mexican patent grant covering its liposomal Annamycin technology, the issuance of 888,400 shares through an at-the-market offering in September 2026, and a resulting reduction in the exercise price of its Series I Warrants.
Key Highlights
- Mexican Patent Granted: The Mexican Patent Office granted Patent No. 436849 covering the company's lung-targeted liposomal Annamycin technology, according to the filing.
- ATM Shares Issued: The company issued 888,400 shares of common stock through its at-the-market offering in September 2026, generating aggregate gross proceeds of $0.48 million.
- Shares Outstanding: Following the ATM issuances, the company reported 20,385,780 shares of common stock outstanding.
- Series I Warrant Price Reduced: The exercise price of the Series I Warrants was reduced from $0.75 per share to $0.51 per share, triggered by the ATM share issuances, per the anti-dilution provisions of those warrants.
- Series I Warrant Scale: The Series I Warrants, issued August 3, 2026, cover up to 37,130,001 shares of common stock and expire on the five-year anniversary of the closing date.
- ATM Agreement Partner: The at-the-market offering is conducted through Roth Capital Partners, LLC under an At Market Offering Agreement entered into in July 2025.
Moleculin Biotech Discloses Patent Win and Warrant Price Adjustment
Moleculin Biotech, Inc. (NASDAQ:MBRX), headquartered in Houston, Texas, filed a current report disclosing two developments. Under Item 7.01, the company announced that the Mexican Patent Office granted Patent No. 436849, which the company characterized as "further strengthening the Company's global intellectual property portfolio protecting its proprietary lung-targeted liposomal Annamycin technology." The press release announcing the grant was attached as Exhibit 99.1 and incorporated by reference into the filing.
Under Item 8.01, the filing detailed activity under the company's existing At Market Offering Agreement with Roth Capital Partners, LLC, originally entered into in July 2025. In September 2026, the company issued 888,400 shares of common stock through that facility for aggregate gross proceeds of $0.48 million. The filing states that after these issuances, the company will have 20,385,780 shares of common stock outstanding.
The filing also disclosed a change to the terms of the Series I Warrants issued August 3, 2026, in a public offering. Those warrants initially entitled holders to purchase up to 37,130,001 shares of common stock at $0.75 per share and carry anti-dilution provisions that lower the exercise price when the company issues common stock or equivalents below the then-current exercise price, subject to a floor price and certain exempt issuances. As a result of the ATM share issuances, the filing states the exercise price of the Series I Warrants was reduced to $0.51 per share.
What Was Disclosed
Moleculin Biotech's September 23, 2026, filing reported a Mexican patent grant for its Annamycin technology, the issuance of 888,400 shares raising $0.48 million gross through its ATM facility, and a reduction in the Series I Warrant exercise price from $0.75 to $0.51 per share.



Please wait processing your request...